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1. Introduction 
Metastasis is a spread of cancer cells to a distant location from the primary tumor. This 
process involves a complex series of events similar to those that occur during inflammation. 
The events of metastasis can be divided into four major steps. First, cancer cells proliferate 
and transform to acquire motility and ability to invade basement membrane to reach blood 
vessels. Second, cancer cells penetrate blood vessels due to increased vascular permeability 
facilitated by inflammatory mediators and enter the circulation. Third, in the circulation 
cancer cells are shielded by host cells (platelets and neutrophils) to escape surveillance by 
immune cells and survive shear forces of the bloodstream. Next, integrin-mediated arrest of 
circulating cancer cells occurs on the endothelial surface before extravasation. Once cancer 
cells extravasate, heparanase from cancer cells degrades heparan sulfates of the extra 
cellular matrix. The cleavage of heparan sulfates release growth factors that stimulate cancer 
cell growth as well as angiogenesis. 
The Receptor for Advanced Glycation Endproducts (RAGE) belongs to the immunoglobulin 
superfamily of cell surface molecules. The receptor’s name, RAGE, was coined for its ability 
to bind its first described ligand, advanced glycation end products (AGEs), which 
accumulate in physiological (aging) and pathological disorders such as diabetes (Schmidt et 
al., 1992). RAGE is a pattern recognition receptor for its ligation to structurally unrelated 
ligands that include Mac-1, HMGB1 and S100 /calgranulins. Similar to immunoglobulin, 
RAGE contains an extracellular structure with a V-type binding region and two C-type 
regions. Immediately following the C-type region is a transmembrane region and a short 
cytoplasmic domain (Fig. 1). The important roles played by RAGE in inflammation, 
diabetes, Alzhiemer’s disease and cancer have been discussed in detail (Ellerman et al., 2007; 
Logsdon et al., 2007; Schmidt et al., 2001; Sims et al., 2010; Tang et al., 2010). RAGE is 
ubiquitously expressed in tissues and inflammatory cells at low levels in homeostasis and its 
expression is increased in stress conditions. RAGE expression is observed in many tumors, 
including brain, breast, colon, lung, prostate, pancreatic, ovarian cancers, lymphoma and 
melanoma (Hsieh et al., 2003; Logsdon et al., 2007) and elevated levels of RAGE have been 
reported in colon (Sasahira et al., 2005), prostate (Ishiguro et al., 2005) and gastric cancers 
www.intechopen.com
 
Research on Melanoma: A Glimpse into Current Directions and Future Trends 
 
82
(Kuniyasu et al., 2002). In contrast, RAGE levels are down-regulated in lung cancer relative 
to levels in the normal lung tissue. These observations have led to studies to delineate the 
pathophysiologic involvement of RAGE in cancer. Notably, AGEs are involved in 
development and progression of cancers (Abe et al., 2007; Sebekova et al., 2007).  
 
 
Fig. 1. RAGE domains and ligands involved in cancer. RAGE has ligand-binding V-domain 
followed by two C-domains of similar to immunoglobulins, a transmembrane region and 
cytoplasmic tail.  
Heparin was discovered in 1916 (McLean, 1916)}, and has been used almost exclusively as 
an anticoagulant in medicine. However, shortly after its initial discovery, it was reported 
that heparin had an inhibitory effect on tumor growth in animals (Goerner, 1930). This 
initial observation led to intensive investigation with regard to heparin’s anticancer and 
anti-metastatic properties (Casu et al., 2010; Casu et al., 2008; Hettiarachchi et al., 1999; 
Kragh et al., 2005; Kragh & Loechel, 2005; Lapierre et al., 1996; Lever & Page, 2002; Ono et 
al., 2002; Ornstein & Zacharski, 1999; Smorenburg et al., 1996; Stevenson et al., 2005; 
Stevenson et al., 2007; Vlodavsky et al., 2006; Yip et al., 2006; Yoshitomi et al., 2004). The 
usefulness of heparin as an anticancer drug has been hindered by its anticoagulant effect at 
therapeutic doses required to inhibit cancer growth and spread. The potential of heparin as 
an anticancer and anti-inflammatory agent led to discovery of a number of low or 
nonanticoagulant heparins produced by chemical modifications of the heparin polymer 
itself (Irimura et al., 1986; Lundin et al., 2000; Vlodavsky et al., 1994), sulfation of other 
natural polymers (Borgenstrom et al., 2007; Kaeffer et al., 1999; Miao et al., 1999) and 
sulfated heparin-like polymers produced synthetically (Wellstein et al., 1991; Zugmaier et 
al., 1992). Studies with heparanoids have been limited to animal models. In human studies, 
heparin has proven beneficial in cancer treatment but its anticoagulant activity has limited 
its use.  
Herein we describe a nonanticoagulant 2-O, 3-O desulfated heparin (ODSH) that retains the 
anti-inflammatory activities of heparin, including inhibition of P- and L-selectins, 
heparanase, cationic neutrophil proteases, activation of nuclear factor-κB (NF-κB) and 
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ligation of RAGE by HMGB-1, AGEs and S100 calgranulins (Barry et al., 2010; Lapierre et al., 
1996; Rao et al., 2010; Thourani et al., 2000). Also, we describe the first clinical experience 
with this modified heparin, which has proven safe and low in anticoagulant activity in 137 
humans tested to date. Moreover, we present studies demonstrating that ODSH does not 
cause heparin-induced thrombocytopenia (HIT), a thrombotic syndrome occurring in 3% of 
individuals receiving heparins (Arepally & Ortel, 2010).  
2. Methods 
2.1 Production of ODSH 
ODSH is a heparin derivative produced for human use under cGMP conditions by the 
leading U.S. commercial manufacturer of bulk pharmaceutical grade USP heparin, Scientific 
Protein Laboratories (Wanaukee, WI). It is synthesized by cold alkaline hydrolysis of USP 
porcine intestinal heparin, as reported (Fryer et al., 1997), which removes the 2-O sulfate 
groups from iduronic acid residues and the 3-O sulfate groups from the glucosamine 
residues of the heparin backbone, The N-sulfates,  6-O sulfates, and carboxylates remain 
intact (Fig.2).  
 
 
Fig. 2. Sulfate position in disaccharide units of ODSH in comparison to heparin. 
2.2 Phase I clinical trials 
Two INDs have been opened for intravenous ODSH:  #71,356 (under which Phase I safety 
trials were conducted and pediatric protein losing enteropathy is being studied) and #72,247 
(inactive, for a phase II trial in exacerbations of COPD). In the 137 humans who have 
received intravenous ODSH by bolus and constant infusion for up to 5 days, there have 
been no serious adverse events, and no decrease in platelet count in any subject to suggest 
occurrence of HIT, which might have been expected in 2-4 (2-3%) subjects. In Phase I human 
safety studies (Rao et al., 2010) bolus ODSH was administered safely in doses as high as 20 
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mg/kg, resulting in lower activated partial thromboplastin times (aPTT) than the usual 
anticoagulation bolus of unfractionated heparin (80 U/kg, i.e., 0.5 mg/kg at the usual 160 
U/mg anti-Xa activity of USP heparin). As part of the Phase I evaluation, ODSH was 
infused as a bolus of 8 mg/kg followed by continuous intravenous infusion of 0.5 mg/kg/h, 
adjusted to maintain an aPTT between 40 and 45 seconds (0.64 to 1.39 mg/kg/h final 
infusion rate). 
2.3 Cell culture 
U937 monocytes were grown in suspension culture at 37° C in humidified 5% CO2-95% air 
in RPMI-1640 supplemented with 10% heat inactivated FBS, 2 mM L-glutamine, 1 mM 
sodium pyruvate, 0.1 mM MEM non-essential amino acids, 100 units/mL penicillin and 100 
μg/mL streptomycin. Experiments were performed on cells from passages 1-5. B16F10.1 
melanoma cells were grown in Dulbecco’s modified Eagle’s medium, 10% fetal bovine 
serum, 100 U/mL penicillin, 100 U/mL streptomycin, 2 mM glutamine and 1 mM sodium 
pyruvate. 
2.4 Adhesion assays 
2.4.1 Cell surface binding assays   
The effect of heparinoids on binding of U937 monocytes to P-selectin or RAGE was studied 
in high-bind micro plates coated with 8 μg/mL protein A (50 μL/well) in 0.2 M carbonate-
bicarbonate buffer (pH 9.4). Plates were washed with phosphate buffered saline (PBS) 
containing 1% BSA (PBS-BSA), and P-selectin-Fc or RAGE-Fc chimera (50 μL containing 1 
μg) was added to each well and incubated for 2 h at room temperature or overnight at 4° C, 
respectively. Following incubation, wells were washed twice with PBS-BSA. Fifty μL of 
heparinoids (0 to 1,000 μg/mL) serially diluted in 20 mM HEPES buffer (containing 125 mM 
NaCl, 2 mM calcium and 2 mM magnesium) were added to each well and incubated at 
room temperature for 15 min. As a negative control, 50 μL of 10 mM EDTA was added to 
select wells to prevent cell binding through sequestration of calcium. At the end of the 
incubation period, 50 μL of U937 cells (105 cells/well, calcein-labeled according to 
manufacturer’s instructions) were added to each well and plates were incubated an 
additional 30 min at room temperature. The wells were then washed thrice with PBS, and 
bound cells were lysed by addition of 100 μL of Tris-Triton X-100 buffer. Fluorescence was 
measured on a microplate reader using excitation of 494 nm and emission of 517 nm.  
2.4.2 Solid phase binding assays  
Two types of ELISAs were performed, one to observe the binding between RAGE and its 
ligands, including CML-BSA, HMGB-1 and S100b, and a competitive ELISA to study the 
ability of ODSH to inhibit/compete for RAGE binding to its ligands.  
To confirm RAGE binding to its ligands, polyvinyl 96-well plates were coated with 5 
μg/well of specific ligand (CML-BSA, HMGB-1 or S100b calgranulin). Plates were incubated 
overnight at 4° C and washed thrice with PBS-0.05% Tween-20 (PBST). Next, 50 μL of RAGE 
from the dilution series ranging from 0.001 to ~ 6 nM was transferred to each respective 
ligand-coated well and incubated at 37° C for 1 h. Wells were then washed four times with 
PBST. To detect bound RAGE, 50 μL of anti-RAGE antibody (0.5 μg/mL) was added to each 
well, the mixture was incubated for 1 h at room temperature, and wells were washed again 
four times with PBST. HRP-conjugated secondary antibody (50 μL per well) was added, 
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wells were incubated for 1 h at room temperature, and then washed once with PBST. A 
colorimetric reaction was initiated by addition of 50 μL of TMB and terminated after 15 min 
by addition of 50 μL of 1 N HCl. Absorbance at 450 nm was read using an automated 
microplate reader. Binding affinity (KD) was determined from the plot of absorbance values 
versus concentrations of RAGE.  
RAGE binding to glycated ECM proteins, collagen-I, collagen -IV, fibronectin and laminin 
coated plates were used. Plates were incubated with 100 µL of 0.15 M glyoxylic acid + 0.45 
M sodium cyanoborohydride mixture at 37 °C for 24 hours. At the end of incubation period, 
the plates were washed with PBST and used for RAGE binding as described above. 
For studies of the effect of ODSH or heparin on RAGE binding to its ligands, polyvinyl 96-
well plates were coated with specific ligand as described above. Separately, a constant 
amount of RAGE-Fc chimera (100 μL containing 0.5 μg/mL in PBST containing 0.1% BSA) 
was incubated with an equal volume of serially diluted ODSH or heparin (0.001 to 1,000 
μg/mL in PBST-BSA) overnight at 4° C. The following day, 50 μL of RAGE-heparinoid mix 
was transferred to each respective ligand-coated well and incubated at 37° C for 2 h. Wells 
were then washed four times with PBST. Bound RAGE was detected as described above. 
Absorbance at 450 nm was plotted against concentration of ODSH or heparin. The IC50 
values were obtained using non-linear regression analysis.  
2.5 Elastase and cathepsin G activity assay 
The inhibitory activity of heparin and ODSH against HLE and cathepsin G was monitored 
using the specific chromogenic substrates Suc-Ala-Ala-Val-pNA and Suc-Ala-Ala-Pro-Phe-
pNA, respectively, according to methods previously described (Fryer et al., 1997).  
2.6 Mouse model of melanoma lung metastasis 
Lung metastasis from melanoma was studied using protocols previously reported by the 
Varki group (Stevenson et al., 2005). Animal use and husbandry followed protocols 
approved by the IACUC at the University of Utah. Confluent B16F10 melanoma cells (70-
80%) were harvested by brief exposure to trypsin, and washed twice with serum-free 
medium prior to injection. Living cells were counted with Trypan blue staining prior to 
injection to insure > 95% viability. Female C57BL/6J mice (n = 6 per group) were injected 
subcutaneously with 100 μL PBS, heparin (30 mg/kg) or ODSH (30 mg/kg). Thirty min 
later, 5 x 105 B16F10 cells in 200 μL medium were injected intravenously into the lateral tail 
vein. Mice from each group were injected in alternating order, and cells were resuspended 
by gently flicking the tube before aspirating the sample for each injection. Twenty-seven 
days after injection, surviving mice were euthanized. The lungs were removed, perfused 
intra-tracheally with 10% buffered formalin and photographed. Visible tumor foci were 
counted independently by two different laboratory personnel blinded with regard to 
treatment groups, and metastasis quantified in terms of the number of black spots.  
3. Results and discussion 
3.1 ODSH is a non-anticoagulant heparin that is manufactured at industrial scale and 
safe from heparin induced thrombocytopenia 
The ODSH was manufactured as described in Methods section. Seven serial 1-2 kg batches 
of material have shown an average molecular mass of 11.7 ± 0.3 kg kDa. ODSH has low 
affinity for anti-thrombin III (KD = 339 μM or 4 mg/mL vs. 1.56 μM or 22 μg/mL for 
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heparin) consistent with its low anticoagulant activity. Serial batches of ODSH 
demonstrated consistently reduced USP (7 ± 0.3 U of anticoagulant activity/mg), anti-Xa 
(1.9 ± 0.1 U/mg), and anti- IIa (1.2 ± 0.1 U/mg) activities, compared with those of heparin 
(165-190 U/mg activity for all 3 assays). The current clinical formulation that was used in 
137 humans (54 normal and 83 ill patients) is a sterile-filled 20 mL glass vial containing an 
isotonic 50 mg/mL solution of ODSH in buffered saline. This formulation is cGMP 
manufactured by Pyramid Laboratories (Costa Mesa, CA). Chemistry and Manufacturing 
processes are already on file with the FDA in two INDs. A complication of heparin is HIT, 
which occurs in subjects who produce an activating antibody to the heparin-platelet factor 4 
(PF4) complex on the platelet surface, causing thrombocytopenia and thromboembolism 
(Arepally & Ortel, 2010). In standard serotonin release assays (SRA) performed with human 
antibodies to the heparin-PF4 complex, heparin triggered release of 14C-serotonin from 
normal platelets (Fig 3), but ODSH did not trigger HIT at any concentration (Rao et al., 
2010).  
 
 
Fig. 3. ODSH does not trigger platelet activation in the serotonin release assay. Normal 
platelets were loaded with 14C-serotonin and incubated with serum from 3 patients with 
heparin-PF4 antibodies. Platelets were activated by heparin as a positive control (≥ 20% 
serotonin release). Rao et al., Am J Physiol Cell Physiol (2010) Am Physiol Soc, used with 
permission. 
3.2 ODSH is safe to use in humans 
Two INDs have been opened for intravenous ODSH:  #71,356 (under which Phase I safety 
trials were conducted and pediatric protein losing enteropathy is being studied) and #72,247 
(inactive, for a phase II trial in exacerbations of COPD). In the 137 humans who have 
received intravenous ODSH by bolus and constant infusion for up to 5 days, there have 
been no serious adverse events, and no decrease in platelet count in any subject to suggest 
occurrence of HIT, which might have been expected in 2-4 (2-3%) subjects (Arepally & Ortel, 
2010). In Phase I human safety studies (Rao et al., 2010) bolus ODSH was administered 
safely in doses as high as 20 mg/kg, resulting in lower activated partial thromboplastin 
times (aPTT) than the usual anticoagulation bolus of unfractionated heparin (80 U/kg, i.e., 
0.5 mg/kg at the usual 160 U/mg anti-Xa activity of USP heparin). As part of the Phase I 
evaluation, ODSH was infused as a bolus of 8 mg/kg followed by continuous intravenous 
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infusion of 0.5 mg/kg/h, adjusted to maintain an aPTT between 40 and 45 seconds (0.64 to 
1.39 mg/kg/h final infusion rate). This protocol achieved anti-inflammatory plasma ODSH 
concentrations (≥ 10-20 μg/mL) at doses that did not cause anticoagulation (Fig 4). 
 
      
 
Fig. 4. ODSH infusion in human volunteers achieves anti-inflammatory concentrations 
before producing anticoagulation. A. Mean (± SD) plasma ODSH levels during study drug 
infusion, measured by an automated GLP validated assay (Rao et al., 2010). B. Mean (± SD) 
aPTT and change in prothrombin time (PT) during study drug infusion. C. Relationship 
between plasma ODSH and change in aPTT from baseline during the 3 day infusion of 8 
mg/kg followed by 0.5 mg/kg/h adjusted to maintain aPTT between 40 and 45 seconds. 
Rao et al., Am J Physiol Cell Physiol (2010) Am Physiol Soc, used with permission. 
3.3 ODSH has anti-metastatic and anti-inflammatory activities in vitro 
Despite low anticoagulant activity, ODSH retains the strong, broad anti-inflammatory 
activities and antimetastatic activities of heparin. In metastasis, cancer cells disseminate into 
the blood circulation and interact with other circulating cells like leukocytes and platelets 
and also endothelium of vascular wall by selectin-mediated adhesion. The family of 
selectins includes, P-, L- and E-Selectin, which are expressed on activated platelets, 
leukocytes and endothelium. Tumor cells express mucins, which are the ligands for 
selectins, on the cell surface and facilitate cell-cell adhesion. The involvement of selectins in 
metastasis has been shown in selectin-deficient mouse models (Borsig et al., 2002; Kim et al., 
1998; O et al., 2002). Several studies have shown that heparin and heparinoids inhibit 
selectin-mediated cell adhesion, an important phase of metastasis (Borsig, 2010; Borsig et al., 
2001; Borsig et al., 2002; Gao et al., 2006; Ma & Geng, 2000; Maraveyas et al., 2010; Stevenson 
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et al., 2005; Stevenson et al., 2007; Varki, 2007; Wahrenbrock et al., 2003; Wei et al., 2004). To 
investigate the antimetastatic potency of ODSH, we used U937 cells, a human monocytic 
leukemia cells. U937 cells express P-selectin ligand, P-selectin glycoprotein ligand-1 (PSGL-
1), that functions similar to mucins. We tested the ODSH ability to competitively displace 
fluorescent-labeled U937 cells adherence to P-selectin via PSGL-1. ODSH inhibited P-selectin 
with an IC50 of 1.1 μg/mL consistent with that of values reported byWang (Wang et al., 
2002), who demonstrated that ODSH also inhibits L-selectin-mediated adhesion with an IC50 
of 3 μg/mL, versus 0.4 μg/mL for heparin (Wang et al., 2002) (Fig. 5). 
 
 
Fig. 5. Anti-inflammatory and anti-metastatic profile of ODSH. The 50% inhibitory 
concentrations (IC50 values) of ODSH to interrupt the receptor ligand pairs, P-
selectin/PSGL-1, RAGE/Mac-1, RAGE/CML-BSA, RAGE/S100B and RAGE/HMGB1, 
interaction are higher than that of heparin. Nonetheless, the IC50 concentrations of ODSH 
required to inhibit HLE, cathepsin G and heparanase activities, the key enzymes involved in 
the inflammation and metastasis, are similar to the values for heparin. The IC50 values of 
ODSH are higher than that of heparin suggesting that ODSH has lower inhibitory potential 
than heparin, but the values are much lower than achievable plasma concentration (~200 
µg/mL) in humans (see Fig 4). Heparanase data is from (Lapierre et al., 1996). 
Though RAGE binds to disparate ligands, we will discuss only the ligands AGE, HMGB1 
and S100B that have been evaluated for their role in cancer. RAGE and its ligands are co-
expressed in many tumors and the expressed ligands are secreted causing triggering of 
cellular signaling pathways. This results in expression of cytokines, growth factors, 
transcription factors, adhesion molecules and NF-kB (Sparvero et al., 2009). Therefore we 
will focus on the interruption of RAGE-ligand interaction with ODSH. 
Several in vitro studies have shown that AGE stimulates growth, proliferation and invasion 
of cancer cells including melanoma cells (Abe et al., 2004; Yamamoto et al., 1996; Zill et al., 
2003; Zill et al., 2001). AGEs are found in extracellular matrix (ECM) proteins (Ling et al., 
1998; Mizutari et al., 1997) that can interact with RAGE on tumor cells and enhance RAGE 
expression causing damage to surrounding tissues. We therefore tested the binding of 
native and glycated ECM proteins (collagen I, collagen IV, fibronectin and laminin) to 
RAGE. Results indicate that RAGE binds to native ECM protein with a strong affinity but 
the affinity is negligibly decreased with glycated ECM proteins.  Overall, the KD values of 
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RAGE for different ECM proteins are less than 100 ng/mL or <1nM suggesting RAGE on 
tumor cells might play a role in tumor cell spreading (Fig 6).  
 
 
Fig. 6. RAGE binds to AGE-ECM proteins. RAGE binding to ECM proteins was analyzed as 
described in Methods Section. RAGE bound to native Collagen I, Collagen IV and 
fibronectin with same affinity but with a lesser affinity to Laminin. The affinity of RAGE for 
glycated ECM decreased for all the ECM proteins studied but the affinity constants suggest 
that RAGE binds strongly to ECM proteins even in modified conditions. 
In addition, AGE-CML is a common AGE found in vivo (Reddy et al., 1995) and has been 
detected in tumor tissues (van Heijst et al., 2005). Therefore, we tested potential of ODSH to 
disrupt the binding between CML-BSA and RAGE as described in methods section. We 
observed that RAGE bound to CML-BSA with strong affinity (KD 0.43 nM) and ODSH 
inhibited the ligation of CML-BSA with IC50 of 8.6 µg/mL (Fig 5). 
HMGB1 is another ligand for RAGE and both HMGB1 and RAGE have been shown 
elevated in tumors, including melanoma, colon, prostate, breast and pancreatic cancers 
(Brezniceanu et al., 2003; Ellerman et al., 2007; Sparvero et al., 2009). Earlier studies by 
Huttunen et al. suggested that RAGE/HMGB1 signaling might be associated with 
metastasis (Huttunen et al., 1999; Huttunen et al., 2000). Taguchi et al. found that blockade 
of HMGB-RAGE signaling suppressed tumor growth as a result of decreased cell migration 
and invasiveness rather than proliferation or apoptosis (Taguchi et al., 2000). HMGB1 alone 
or by interaction with NF-kBp65 has been shown to bind specific region of melanocyte 
inhibitory activity (MIA) promoter in melanocytes and increase the expression of MIA 
protein, which enhances migration and invasion of tumor cells (Poser et al., 2003; Sasahira et 
al., 2008). HMGB1 was isolated using heparin-sepharose chromatography (Rauvala & 
Pihlaskari, 1987) and later was identified to contain a heparin-binding sequence in its amino 
terminus, suggesting its affinity for heparin (Cardin & Weintraub, 1989). Consistent with 
these observations, HMGB1 also interacted with carbohydrate chain of syndecan and 
facilitated cell migration (Rauvala & Rouhiainen, 2010). Syndecan is expressed in normal 
tissues and tumor tissues but the role of HMGB1 interaction with syndecan in physiological 
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and pathological conditions is not known (Rauvala & Rouhiainen, 2010). Since ODSH is 
derived from heparin, we tested whether ODSH can interrupt the RAGE-HMB1 ligation. 
Though HMGB1 binds to RAGE with high affinity (KD 0.64nM), ODSH inhibited RAGE-
HMGB1 interaction with an IC50 of 0.23 µg/mL (Figs. 5 and 7). 
 
 
Fig. 7. ODSH and heparin inhibit binding of HMGB-1 to RAGE. HMGB-1 binding to RAGE-
Fc chimera was studied using ELISA techniques as described in Methods. RAGE bound to 
immobilized HMGB-1 in a saturable fashion (inset) with a KD of 0.64 nM. ODSH (●) and 
heparin (○) inhibit binding of recombinant HMGB-1 to RAGE with IC50 values of 0.23 and 
0.04 μg/mL, respectively. Rao et al., Am J Physiol Cell Physiol (2010) Am Physiol Soc, used 
with permission. 
S100 proteins are calcium dependent proteins of the EF-hand (helix-loop-helix) type that are 
differentially located and differentially expressed in a wide variety of cells (Donato, 1999; 
Donato, 2001; Donato et al., 2009). Among the 25 S100 protein identified, S100b is unique in 
its location on chromosome 21q22.3 and first one of the group found to ligate to RAGE 
(Hofmann et al., 1999). S100b is highly expressed in melanoma and considered as possible 
biomarker for the prognosis of the disease (Harpio & Einarsson, 2004; Salama et al., 2008). 
We studied the binding affinity of S100b to RAGE. RAGE ligated to S100b with a KD of 0.45 
nM, a value much lower than the affinity range reported (reviewed in (Leclerc et al., 2009)). 
ODSH inhibited the binding of RAGE to S100b with IC50 value of 4.23µg/mL. (Fig 5). 
HMGB-1 is released into extracellular milieu as a result of necrosis, apoptosis and secretion. 
Only HMGB1 released by necrotic cells demonstrates cytokine activity, recruits leukocytes 
and activates endothelial cell adhesion molecules such as selectins (Dumitriu et al., 2005; 
Lotze & Tracey, 2005). In cancer, tumor cells undergoing stress are susceptible to death 
because of factors that include hypoxia, nutrient deprivation and or anticancer treatments 
(Kepp et al., 2009). These dying cancer cells become a source of HMGB1 (Dong Xda et al., 
2007; Scaffidi et al., 2002). Orlova et al (Orlova et al., 2007)) have shown that HMGB1-
induced Mac-1 dependent neutrophil recruitment requires the presence of RAGE on 
neutrophils but not on endothelial cells. Interestingly, three proteins, HMGB1, Mac-1 and 
RAGE bind to heparin (Diamond et al., 1995; Hanford et al., 2004; Rauvala & Pihlaskari, 
1987). We therefore tested Mac-1 dependent binding of U937 cells to immobilized RAGE. 
ODSH inhibited the adherence of U937 cells to RAGE with IC50 values of 0.11 µg/mL  
(Fig 5). 
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3.4 ODSH Prevents metastasis in vivo 
The vitro studies described above suggested that ODSH, similar to heparin, might interrupt 
key receptor-ligand interactions involved in metastasis. We therefore investigated the effects 
of ODSH in experimental melanoma lung metastasis. Heparin significantly decreased lung 
metastasis at 28 days after melanoma injection, but the same dose of ODSH provided 
substantially greater reduction of lung metastasis (Fig 8A). ODSH also significantly 
improved 28-day survival. In contrast to 70% mortality in mice treated with PBS, ~ 70% of 
ODSH-treated mice survived the experiment (Fig 8B). 
 
 
Fig. 8. ODSH inhibits melanoma lung metastasis. Female C57BL/6J mice (n = 6/group) were 
injected SQ with 100 μL PBS, 30 mg/kg heparin, or 30 mg/kg ODSH. Thirty min later, 5 x 
105 B16F10 melanoma cells were injected IV into the tail vein. 27 days later surviving mice 
were euthanized and lungs were removed, fixed, stained and assessed for metastasis by 2 
independent observers. A. Heparin (*P < 0.05 vs PBS) or ODSH (**P < 0.01 vs PBS) 
significantly reduced metastasis. B. SQ heparin showed little effect on lung metastatic 
outgrowth but ODSH suppressed metastatic colonization microscopically. C. ODSH 
improved survival (*P < 0.05 vs PBS). Rao et al., Am J Physiol Cell Physiol (2010) Am 
Physiol Soc, used with permission. 
This model is widely used to test the inhibitory capacity of heparin and heparins with no or 
minimal anticoagulant activity in metastasis (reviewed in (Borsig, 2010). The attenuation of 
metastasis was attributed to P-selectin and L-selectin as the experimental mice were 
deficient in selectin but also suggested that there is a selectin-independent mechanism 
involved. It is not clear whether B16 melanoma cells express mucins on the cells surface to 
interact with P-selectin, but the expression of RAGE is observed in melanoma cells 
(Huttunen et al., 2002; Saha et al., 2010). Further, Huttunen et al showed the attenuation of 
metastasis when B16 cells injected with HMGB1 peptide suggesting the RAGE-mediated 
tumor cell invasion can be inhibited by competition with RAGE binding ligand such as 
B 
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ODSH and heparin.  In summary, because ODSH interacts with the many receptors, ligands 
and inhibits enzymes involved in the metastasis, the attenuation of metastasis in the 
experimental model is due to action of ODSH on multiple sites. 
4. Conclusion 
A number of fully anticoagulant heparins are commercially available, but their use as a 
chronic treatment for cancer is dose-limited by their anticoagulant activity. Therapeutic 
anticoagulant doses of heparin or low molecular weight heparin (Hirsh et al., 2001; Koenig 
et al., 1998) do not provide sufficiently high plasma drug concentrations to reliably inhibit 
the selectin-, heparanase- or RAGE-mediated processes (Koenig et al., 1998; Lapierre et al., 
1996; Rao et al., 2010; Wang et al., 2002) that are now understood to be important for 
explaining the benefits of heparins in cancer.  
 
 
 
Fig. 9. Potential interference of low anticoagulant ODSH in metastasis. ODSH 1) inhibits 
heparanse, the enzyme secreted by tumor cells during intravsation and extravsation thus 
prevent spread of the tumor cells, 2) inhibits the tumor cell mucin (P-selectin ligand) 
binding to P-selectin on endothelial cells and platelets, 3) inhibits tumor cell RAGE 
interaction with leukocyte Mac-1, 4) inhibits tumor cell RAGE interaction with its ligands, 
AGE, HMGB1 and S100b, that are either released by tumor cells within cancer micro 
environment or by the leukocytes thus prevent sustained signaling for tumor progression,  
5) inhibits circulating RAGE  ligand interaction with endothelial RAGE. 
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Of the available low anticoagulant heparin derivatives (Casu et al., 2008; Fryer et al., 1997; 
Kragh et al., 2005; Kragh & Loechel, 2005; Lapierre et al., 1996; Ono et al., 2002; Rao et al., 
2010; Stevenson et al., 2007; Wang et al., 2002; Yoshitomi et al., 2004), only ODSH has been 
proven safe from major adverse events in humans (Rao et al., 2010) data on file with FDA) 
and only ODSH is free from the potential to induce HIT (Rao et al., 2010). The concept that 
P-selectin is the key molecule in metastasis is based on the attenuation of metastasis in 
animal models. Because of the complex biology of cancer metastasis, it is not easy to identify 
the specific mediator(s) involved in development of metastatic disease in patients with 
cancer. In such situation, a compound that can simultaneously target multiple mediators 
involved in the diseases might have substantial therapeutic value. We have described that 
non-anticoagulant ODSH, not only targets P-selectin, but additionally is capable of 
inhibiting the RAGE interaction with its multiple structurally unrelated ligands that play 
many biological roles in metastasis (Fig. 9). Thus, the results described herein support the 
notion that low anticoagulant heparin derivatives such as ODSH might prove useful in 
prevention of metastasis in human cancer. 
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